Recruiting
Phase 1

Intravenous Lidocaine

Sponsor:

Wayne State University

Code:

NCT07940387

Conditions

Orthopedic Fractures

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lidocaine infusion

Saline (0.9% NaCl)

Study Details

Brief summary:

In this research study, we will be evaluating whether an anesthesia provider using the method of intravenous lidocaine infusion during the perioperative and immediate postoperative period can provide equal short-term pain control and decrease postoperative opioid consumption compared to traditional opioid utilization. We will also evaluate the effects of intravenous lidocaine on inflammatory mediators such as interleukins and cytokines through timed lab draws. The study hypothesis is that intravenous lidocaine will provide similar pain relief and decrease the amount of post operative opioids used, as well as decrease the amount of inflammatory mediators present compared to conventional post-operative treatment utilizing solely opioids.

Conditions

Orthopedic Fractures

Study ID

NCT07940387

Start date

Sep 16, 2026

Status verified date

Nov, 2026

Completion date

Dec 1, 2027

Anticipated

Primary completion date

Dec 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

\- ASA physical status I-III, males and females >18 years of age and < 85 years of age, scheduled for repair of lower extremity (orthopedic) fracture/s of a single extremity. The type of injury will be documented and categorized- as applicable- in demographic data. The type of fracture will be extracted from the electronic surgical/operative report i.e. preoperative and postoperative diagnosis.

Exclusion Criteria:

  • Contraindication to lidocaine including allergy, substantial hepatic impairment (alanine aminotransferase greater than 120 IU/L or aspartate aminotransferase > 80 IU/L), substantial renal impairment (serum creatinine >2 mg/dL), current history of narcotic abuse, cognitive impairment (any patients who are alert and oriented x2 or less; for example, 0-2), cardiac ejection fraction less than 20% by documented cardiac consultation and evaluation, history of seizure disorders, and patients with documented sensory impairments such as neuropathies, fibromyalgia, and diabetes mellitus with concomitant neuropathies (because these sensory impairments may confound postoperative measurements of pain). Cardiac Ejection Fraction less than 20% further explained: Patients who are admitted to the hospital and scheduled for surgery that are deemed high cardiac risk (by history and physical and/or per patient) routinely have echocardiograms per standard of care, and if necessary further cardiac consultations and 'work ups' are performed at Detroit Receiving Hospital. With the thorough history and physical that is required, the results will be available prior to surgery and anesthesia. If a patient has demonstrated 'no cardiac risk factors' after a complete history and physical examination, they will be assumed to have a normal ejection fraction. Pregnant women will also be excluded as there have been no controlled studies in humans investigating the potential effects of intravenous lidocaine during pregnancy. All patients undergo a serum or urine HCG test prior to surgery, and these will be evaluated by the researchers.

Patients under the age of 18 will be excluded due to recent studies finding adverse reactions, although mild, appear to be common in children. Oxygen saturation of <95% on room air will be excluded per the lidocaine package insert. Weight of 150 kg (330 lbs) will be excluded per the lidocaine package insert.

Study Design

Enrollment

66 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

placebo comparator: Control Group - Saline Infusion

Saline bolus and infusion

experimental: Intervention - IV Lidocaine Group

Lidocaine bolus and infusion

Interventions

Lidocaine infusion

A Lidocaine (LID) bolus 2mg/kg followed by an infusion rate of 2 mg/kg/hr.

Saline (0.9% NaCl)

Saline infusion

Primary outcome measure

  • Morphine equivalents [ Time Frame: from enrollment to 14 days postoperative ]
  • Interleukin 6 (IL-6) [ Time Frame: 1, 6, 24 and 48 hours postoperative ]
  • Interleukin 8 (IL-8) [ Time Frame: 1, 6, 24 and 48 hours postoperative ]
  • Complement C3a [ Time Frame: 1, 6, 24 and 48 hours postoperative ]
  • Visual Analogue Pain Score [ Time Frame: Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative. ]

Central Contacts and Locations

Locations

Detroit Receiving Hospital

Recruiting

Detroit, Michigan, United States, 48201

Contacts

Jessica Phillips, PhD, CRNA

313-577-9239fy9015@wayne.edu

Mary Golinski, PhD, CRNA

248 364 8776golinski@oakland.edu

Principal Investigator:

Jessica Phillips, PhD, CRNA

More Information

Sponsor

Wayne State University

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • orthopedic fractures
  • IV lidocaine
  • trauma
  • interleukin
  • complement

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Wayne State University on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.